Disclosures: Brett McGettigan: Nothing to Disclose, Dawood Al Dawood: Nothing to Disclose, Harmeet Malhi: MERCK: Consultant, Vijay Shah: Boehringer Ingelheim: Consultant, GSK: Consultant, GENFIT SA: Consultant, Intercept Pharmaceuticals, Inc.: Advisor, Korro Bio, Inc.: Consultant, Mallinckrodt Pharmaceuticals: Advisor, Novo Nordisk A/S: Consultant, Resolution Therapeutics, Ltd.: Advisor, Seal Rock Therapeutics, Ltd.: Consultant, Surrozen: Advisor 1569 HEPATIC METHYLTRANSFERASE PROTEINS MEDIATE PNPLA3-I148M-DRIVEN LIPID DROPLET DYNAMICS IN FATTY LIVER Xinshou Ouyang 1 Yan Zhang 2 Suyavaran ARUMUGAM 2 Shi-Ying Cai 1 Wanqing Liu 3 Wajahat Mehal 1 , 1 Yale University, 2 Yale School of Medicine, 3 Wayne State University Background: The accumulation of Lipid droplets (LDs) characterizes fatty liver in metabolic dysfunction-associated fatty liver disease (MAFLD) and alcohol-associated liver disease (ALD), closely tied to genetic variants, particularly PNPLA3 -I148M
RBCs are exposed to extreme oxidative stress as they age in circulation, traveling from lung alveoli with 100 mmHg pO2 to peripheral capillaries with as low as 20-40 mmHg pO 2
tb survival and effector responses against the pathogen inside RIF and RIF+NAC-treated granulomas from healthy subjects RIF is another important first line antibiotic generally used with INH to treat TB clinically
Cannabidiol: State of the art and new challenges for therapeutic applications
